SEC Form 4 · accession 0001209191-17-013435
NANOPHASE TECHNOLOGIES Corp · NANX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
George A Vincent
Director
Period of report
Feb 21, 2017
Accepted (ET)
Feb 22, 2017 · 5:30 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000883107
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $0.68 | Feb 21, 2017 | A | 10,000 | A | Feb 21, 2018 | Feb 21, 2027 | Common Stock | 10,000 | 10,000 | D |
| Stock Option (right to buy)F1 | $4.48 | holding | — | — | — | Nov 6, 2008 | Nov 6, 2017 | Common Stock | 10,000 | 10,000 | D |
| Stock Option (right to buy)F1 | $1.36 | holding | — | — | — | Jan 31, 2012 | Jan 31, 2021 | Common Stock | 12,000 | 12,000 | D |
| Deferred Common StockF2,F3,F4 | — | holding | — | — | — | — | — | Common Stock | 2,250 | 12,652 | D |
| Stock Option (right to buy)F1 | $0.30 | holding | — | — | — | Aug 7, 2013 | Aug 7, 2022 | Common Stock | 12,000 | 12,000 | D |
| Stock Option (right to buy)F1 | $0.415 | holding | — | — | — | Feb 14, 2014 | Feb 14, 2023 | Common Stock | 10,000 | 10,000 | D |
| Stock Option (right to buy)F1 | $0.52 | holding | — | — | — | Feb 13, 2015 | Feb 13, 2024 | Common Stock | 10,000 | 10,000 | D |
| Stock Option (right to buy)F1 | $0.44 | holding | — | — | — | Feb 18, 2016 | Feb 18, 2025 | Common Stock | 9,000 | 9,000 | D |
| Stock Option (right to buy)F1 | $0.42 | holding | — | — | — | Feb 23, 2017 | Feb 23, 2026 | Common Stock | 8,100 | 8,100 | D |
| Stock Option (right to buy)F5 | $0.90 | holding | — | — | — | Nov 17, 2016 | Nov 17, 2026 | Common Stock | 2,250 | 2,250 | D |
| Stock Option (right to buy)F5 | $1.05 | holding | — | — | — | Nov 17, 2016 | Nov 17, 2026 | Common Stock | 2,250 | 2,250 | D |
| Stock Option (right to buy)F5 | $1.18 | holding | — | — | — | Nov 17, 2016 | Nov 17, 2026 | Common Stock | 2,250 | 2,250 | D |
| Stock Option (right to buy)F5 | $0.84 | holding | — | — | — | Nov 17, 2016 | Nov 17, 2026 | Common Stock | 2,250 | 2,250 | D |
| Stock Option (right to buy)F5 | $1.85 | holding | — | — | — | Nov 17, 2016 | Nov 17, 2026 | Common Stock | 2,250 | 2,250 | D |
| Stock Option (right to buy)F5 | $1.10 | holding | — | — | — | Nov 17, 2016 | Nov 17, 2026 | Common Stock | 2,250 | 2,250 | D |
| Stock Option (right to buy)F5 | $0.99 | holding | — | — | — | Nov 17, 2016 | Nov 17, 2026 | Common Stock | 2,250 | 2,250 | D |
Explanation of responses
- F1Subject to certain rights and restrictions, beginning on this date, options vest in three equal annual installments.
- F2Each share of deferred common stock represents a right to receive one share of common stock.
- F3The deferred common stock becomes payable upon the reporting person's termination of service as a director of the Company.
- F4Pursuant to such plan, the reporting person elected to defer receipt of such shares and receive a cumulative total of 12,652 shares of deferred common stock which will all be accounted for under the Company's Non-Employee Director Deferred Compensation Plan.
- F5The stock appreciation rights payable upon the reporting person's termination of service as a director of the Company were terminated, with stock options issued with exercise prices equal to the conversion prices of the respective stock appreciation rights. 2,250 were issued with an exercise price of $0.90, 2,250 were issued with an exercise price of $1.05, 2,250 were issued with an exercise price of $1.18, 2,250 were issued with an exercise price of $0.84, 2,250 were issued with an exercise price of $1.85, 2,250 were issued with an exercise price of $1.10, and 2,250 were issued with an exercise price of $0.99.